CSL CSL is a global biopharma company working to create enduring impact for patients and public health. 120+ countries where CSL provides life-saving products to patients Almost 29,000 employees globally US$2.92 dividend per share for FY2026 US$15.8b annual revenue CSL uses its deep expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as haemophilia, immune deficiencies, influenza and iron deficiency anaemia. CSL innovates at every step of the process. It pioneers therapies and vaccines, improves patients’ and donors’ experiences, broadens access to treatments, and tackles complexity at scale through specialised manufacturing processes. Helping address unmet medical needs is what sets CSL apart. CSL’s focus is on diseases where it has a fundamental advantage in understanding the disease and the science; and medicines where it has a high degree of specialist expertise or manufacturing differentiation. CSL Behring CSL Seqirus CSL Vifor 2
RkJQdWJsaXNoZXIy MjE2NDg3